×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu
Nick Langley

Nick Langley

Nick Langley is Managing Director, Co-Founder, and Senior Portfolio Manager at ClearBridge Investments. As a Portfolio Manager, Nick is a member of the investment committees responsible for all global listed infrastructure strategies. He has 26 years of investment industry experience.

Funds / Markets / Property / Video

Public Policy Among Many Tailwinds for Infrastructure

February 15, 2021February 15, 2021 - by Nick Langley

Many factors – from a high-growth, low-inflation, low bond yield environment to climate change initiatives, electric vehicle adoption and grid resilience – are lining up as tailwinds for infrastructure portfolios.

Read More
Funds / Markets / Property

A Smoother Path to Infrastructure Spending

January 21, 2021January 21, 2021 - by Nick Langley

The election of Joe Biden as U.S. president and Democratic control of both the House and the Senate should further boost the focus on infrastructure spending.

Read More
Funds / Markets / Property

Infrastructure Outlook: Greater Outlays to Boost Growth

December 15, 2020 - by Nick Langley

Encouraging developments on the vaccine front late in 2020 and advances in the world’s ability to manage infection rates while still working, learning and spending are positive signs for 2021, and we are constructive on the outlook for global listed infrastructure for several reasons.

Read More
Funds

The Push for Sustainable Infrastructure

October 9, 2020October 9, 2020 - by Nick Langley

The COVID-19 pandemic has meaningfully hit most countries in the world, bringing with it a toll on human lives and livelihoods. As governments move to mitigate the public health crisis and support economies through monetary and fiscal policy, many are asking if governments will stimulate their economies with investments in infrastructure.

Read More

Recently Added

  • Evening Report: Aussie shares edged higher on Friday
  • Coronado Beset By Poor Prices, Higher Costs
  • Resumption of Normal Life No Boon for Kogan
  • Lunch Report: Market at risk to snap 4-week winning streak
  • Relief Rally Sees AMP Bounce off Record Lows
  • Archegos, Greensill the Gifts that Keep on Taking for CS
  • Morning Report: US sharemarkets fell on Thursday
  • Brambles on Track to Meet Full-Year Forecast

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

Do Two A+ Deals Foreshadow THE DEAL?

Licensing deals are the life blood of small pharmaceutical companies, representing their exit from the development of a molecule, often in a staged manner, and a coalescing of the value they have added to a compound. Kazia Therapeutics has done two licensing deals in the space of a month, something unique for an Australian company. In this report, we look at those deals, assess their quality and look at other takeaways they provide.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Star.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the House.

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Flag.

DOWNLOAD RESEARCH REPORT

The EV Megatrend – Responsibly sourced lithium the “new oil”

Lake Resources (LKE.AX) aims to become a major global producer of high quality battery grade lithium carbonate. It holds 100% equity in four significant Argentinian brine assets situated in the Lithium Triangle. LKE is using disruptive lithium extraction technology to produce lithium for sales into the US, Europe and Asia. With its clean tech partner Lilac Solutions, LKE is moving fast to bring a low carbon, low water, low waste, no acid products, light footprint, low-cost and high value project to market.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Plane.